From the INTERNATION **AUTHORITY TECH CENTER 1600/2900** NOTIFICATION OF TRANSMITTAL OF BIOGEN, Inc. **HE INTERNATIONAL SEARCH REPORT** Attn. LINKKILA, Timothy p. OR THE DECLARATION 14 Cambridge Center Cambridge, Ma 02142 (PCT Rule 44.1) UNITED STATES OF AMERICA bate of mailing (day/month/year) 06/03/2001 Applicant's or agent's file referé See paragraphs 1 and 4 below FOR FURTHER ACTION A080PCT International filing date International application No. (day/month/year) 16/08/2000 PCT/US 00/22507 Applicant BIOGEN, INC. et al. The applicant is hereby notified that the International Search Report has been established and is transmitted herewith. Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46): When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report: however, for more details, see the notes on the accompanying sheet. International Bureau of WIPO Where? Directly to the 34, chemin des Colombettes 1211 Geneva 20. Switzerland Fascimile No.: (41-22) 740.14.35 For more detailed instructions, see the notes on the accompanying sheet. The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that: the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices. no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made. 4. Further action(s): The applicant is reminded of the following Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication. Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later). Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II. Name and mailing address of the International Searching Authority Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 Catherine Humbert NL-2280 HV Rijswijk

Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.

Fax: (+31-70) 340-3016

NUIES IU FURM FUI/ISM44V

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international polication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) th claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 *Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers;
 claims 30, 33 and 36 unchanged; new claims 49 to 51 added.*
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- (Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims):
 - *Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added.* or *Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged.*
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	1 Citt Ottillen (ee Notification of Transmittal of Form PCT/ISA/220) as well as	of International Search Report , where applicable, item 5 below.
A080PCT	ACTION	(Fodical) F	right Data (day/month/cost)
International application No.	International filing date (day)	(Earliest) P	riority Date (day/month/year)
PCT/US 00/22507	16/08/200	0	17/08/1999
Applicant			
BIOGEN, INC. et al.			
This International Search Report according to Article 18. A copy is	has been prepared by this International being transmitted to the International f	al Searching Authority and is tr Bureau.	ansmitted to the applicant
This International Search Report X It is also accomp	consists of a total of7 anied by a copy of each prior art docu	sheets. ment cited in this report.	
Basis of the report			
With regard to the langulanguage in which it was	age, the international search was carri filed, unless otherwise indicated unde	ed out on the basis of the inter r this item.	rnational application in the
the international Authority (Rule 2	search was carried out on the basis of (3.1(b)).	a translation of the internation	al application furnished to this
was carried out on the ba	eotide and/or amino acid sequence of asis of the sequence listing:		pplication, the international search
ا ا	international application in written form		
<u> </u>	h the international application in comp	uter readable form.	
	quently to this Authority in written form		
	quently to this Authority in computer re		
international app	at the subsequently furnished written s dication as filed has been furnisned.		
X the statement the furnished	at the information recorded in compute	er readable form is identical to	the written sequence listing has been
2. X Certain claims	were found unsearchable (See Box I).	
	ion is lacking (see Box II).		
- 4With regard to the title,			•
	ved as submitted by the applicant.	* * * * = * =	
the text has bee	n established by this Authority to read	as follows:	
TVI the text has bee	oved as submitted by the applicant.	b), by this Authority as it appe	ars in Box III. The applicant may.
within one mont	th from the date of mailing of this interr	national search report, submit o	comments to this Authority.
6. The figure of the drawings	to be published with the abstract is Fig	gure NO.	None of the figures
as suggested by	• • • • • • • • • • • • • • • • • • •		None of the figures.
	plicant failed to suggest a figure.		
because this fig	pure better characterizes the invention.		

INTERNATIONAL SEARCH REPORT

PCT/US 00/22507

Box III TEXT OF THE ABSTRACT Continuation of item 5 of the first sheet) Receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Form PCT/ISA/210 (continuation of first sheet (2)) (July 1998)

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) $IPC \ 7 \quad C12N \quad C07K \quad A61K$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE, CHEM ABS Data, EMBL

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Y. LAÂBI ET AL.: "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma" EMBO JOURNAL., vol. 11, 1992, pages 3897-3904, XP002156771 OXFORD UNIVERSITY PRESS, SURREY., GB ISSN: 0261-4189 page 3900, right-hand column, last paragraph -page 3902, right-hand column. paragraph 1; figure 8 page 3903, left-hand column, paragraph 2 -paragraph 3 page 3903, right-hand column, last paragraph ————————————————————————————————————	1-15, 17-21

X Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.			
 Special categories of cited documents: 'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or 	 'T' later document published after the international filing date or priority date and not in conflict with the application but - cited-to-understand the principle or theory underlying the invention 'X' document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled 			
other means *P* document published prior to the international filling date but later than the priority date claimed	in the art. *8* document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
22 February 2001	06/03/2001			
Name and mailing address of the ISA	Authorized officer			
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Montero Lopez, B			

5

1	·	١	1	J	00/	LLJU	

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category *	Citation of document, with indication mineral appropriate, of the following passages	
X	MARIE-PIERRE GRAS ET AL.: "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes" INTERNATIONAL IMMUNOLOGY, vol. 7, no. 7, July 1995 (1995-07), pages 1093-1106, XP000971907 abstract page 1096, right-hand column, paragraph 2 -page 1100, left-hand column, paragraph 2 page 1103, right-hand column, paragraph 2 -page 1104, right-hand column, last paragraph	1-15, 17-21
X	WO 99 12964 A (BIOGEN, INC.) 18 March 1999 (1999-03-18) cited in the application page 1, line 3 - line 8 page 26, line 10 -page 27, line 5; claim 20	2,14,15, 19
X	WO 99 12965 A (BIOGEN, INC.) 18 March 1999 (1999-03-18) page 25, line 1 - line 28 page 1, line 4 - line 10	2,14,15, 19
X	PASCAL SCHNEIDER ET AL.: "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747-1756, XP000915409 page 1751, right-hand column, paragraph 3 -page 1752, left-hand column, paragraph 1	1-10, 12-15, 17-19,21
P,X	JANE A. GROSS ET AL.: "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease" NATURE, vol. 404, no. 6781, 27 April 2000 (2000-04-27), pages 995-999, XP002140939	1-15, 17-21
	page 997, left-hand column, paragraph 2 -page 998, right-hand column, paragraph 2	
P,X	JEFFREY S. THOMPSON ET AL.: "BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population " JOURNAL OF EXPERIMENTAL MEDICINE, vol. 192, no. 1, 3 July 2000 (2000-07-03), pages 129-135, XP002156772 the whole document	1-15, 17-21

5

		1 . 0 . , 00 00,	
	ation) DOCUMENTS CONSIDERE DO BE RELEVANT		Relevant to claim No.
ategory *	Citation of document, with indicate, where appropriate, of the relevant passages		lesevant to claim 140.
Р,Х	WO 00 43032 A (BIOGEN, INC.) 27 July 2000 (2000-07-27)		1-5,12, 14,15, 17,18
	claims 10,11,13,16-19,26,30,33,34,38-40,47		
Ρ,Χ	JEFFREY THOMPSON ET AL.: "BAFF interacts with the orphan receptor, BCMA" SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 51, June 2000 (2000-06), page 65 XP000971932 abstract no. 2.6		19
E	WO 00 68378 A (NATIONAL JEWISH MEDICAL AND RESEARCH CENTER) 16 November 2000 (2000-11-16) page 5, line 29 -page 6, line 31 page 7, line 13 -page 9, line 30 page 12, line 25 -page 13, line 10 page 32, line 12 -page 56, line 6; examples 2-6		1-4, 7-15, 19-21
		·	
:			

5

t: e)

o.

a c r b

u h n

INTERNATIONAL SEARCH REPORT

Box I	Observations where certain alms wer found unsearchable (Continuation of item 1 of first sheet)
This Inte	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 1-15, 17 and 18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. X	Claims Nos.: 16 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
	·
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
· - · - <u>-</u>	
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remai	The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9912964	Α	18-03-1999	AU	9315298 A	29-03-1999
MO 3312304	- 7	10 00 1333	AU	9316298 A	29-03-1999
			BR	9812433 A	26-09-2000
			BR	9812634 A	22-08-2000
			CN	1269832 T	11-10-2000
			CN	1270632 T	18-10-2000
			EP	1012270 A	28-06-2000
			EP	1027431 A	16-08-2000
			NO	20001240 A	10-05-2000
			NO	20001242 A	11-05-2000
			PL	339463 A	18-12-2000
			SK	3542000 A	14-08-2000
			WO	9912965 A	18-03-1999
W0 9912965		18-03-1999	AU	9315298 A	29-03-1999
			AU	9316298 A	29-03-1999
			BR	9812433 A	26-09-2000
			BR	9812634 A	22-08-2000
			CN	1269832 T	11-10-2000
			CN	1270632 T	18-10-2000
			EP	1012270 A	28-06-2000
			EP	1027431 A	
			NO	20001240 A	
			NO	20001242 A	
			PL	339463 A	
			SK	3542000 A	
			W0	9912964 A	18-03-1999
WO 0043032	Α	27-07-2000	AU	3214200 A	07-08-2000
W0 0068378		16-11-2000	NON	F	